SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral appliances for the treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. Its flagship product SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs are cleaning tablets, developed to clean oral appliances safely and effectively. In addition, it also provides sleep test at home under the Sunrise brand name. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.2976754255405515 | N/A |
Market Cap | $24.45M | N/A |
Shares Outstanding | 82.15M | 0.01% |
Employees | 0 | N/A |
Shareholder Equity | 22.40M | -19.38% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -3.06 | N/A |
P/S Ratio | 0.43 | N/A |
P/B Ratio | 1.09 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.2416 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $56.57M | N/A |
Earnings | -$5.41M | N/A |
EPS | -0.0974 | N/A |
Earnings Yield | -0.327 | N/A |
Gross Margin | 0.621 | N/A |
Operating Margin | -0.0487 | N/A |
Net income margin | -0.0957 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $42.28M | N/A |
Total Debt | $15.91M | N/A |
Cash on Hand | $8.09M | N/A |
Debt to Equity | $1.21 | 64.08% |
Cash to Debt | 0.5086 | -60.96% |
Current Ratio | $1.50 | 17.45% |